Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis

Expert Opinion on Drug Safety

Volumn 15, Issue 8, 2016, Pages 1133-1146

  Rogliani, Paola ^a   Calzetta, Luigino ^a   Cazzola, Mario ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

adverse events; meta analysis; PDE4 inhibitor; Rofllumilast; safety

Indexed keywords

PLACEBO; ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR;

ARTICLE; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; RISK ASSESSMENT; WEIGHT REDUCTION; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; GASTROINTESTINAL DISEASES; MEDICATION COMPLIANCE; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HUMANS; MEDICATION ADHERENCE; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84975256743     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1199683     Document Type: Article

References (90)

1. K.Fan Chung Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol. 2006 Mar 8;533(1–3):110–117.
2. A.Castro, M.J.Jerez, C.Gil, et al. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses:advances in the development of specific phosphodiesterase inhibitors. Med Res Rev. 2005 Mar;25(2):229–244.
3. D.Spina, L.J.Landells, C.P.Page. The role of phosphodiesterase enzymes in allergy and asthma. Adv Pharmacol. 1998;44:33–89.
4. M.D.Houslay. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci. 2010 Feb;35(2):91–100.
5. C.P.Page, D.Spina. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol. 2011;204:391–414.
6. M.G.Matera, P.Rogliani, L.Calzetta, et al. Phosphodiesterase inhibitors for chronic obstructive pulmonary disease:what does the future hold? Drugs. 2014 Nov;74(17):1983–1992.
7. H.Amschler. Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors. PCT Patent WO95/01338. 1995.
8. A.Hatzelmann, E.J.Morcillo, G.Lungarella, et al. The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235–256.
9. US Food and Drug Administration. FDA approves new drug to treat chronic obstructive pulmonary diseas. [cited 2016 Mar30]. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244989.htm
10. European Medicines Agency. Daxas – Roflumilast. [cited 2016 Mar30]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001179/WC500089626.pdf
11. A.B.Taegtmeyer, J.D.Leuppi, G.A.Kullak-Ublick. Roflumilast–a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD. Swiss Med Wkly. 2012;142:w13628.
12. E.Worndl, E.B.Hunt, M.P.Kennedy, et al. Roflumilast in COPD. Chest. 2015 Jul;148(1):e31.• A report indicating the frequency of adverse events induced by roflumilast in real-world clinical experience.
13. Y.Wan, S.X.Sun, S.Corman, et al. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world. Int J Chron Obstruct Pulmon Dis. 2015;10:2127–2136.
14. G.Lahu, A.Facius. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability. Int J Clin Pharmacol Ther. 2013 Nov;51(11):832–836.
15. H.Hwang, J.Y.Shin, K.R.Park, et al. Effect of a dose-escalation regimen for improving adherence to roflumilast in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2015 Oct;78(4):321–325.
16. T.Yu, K.Fain, C.M.Boyd, et al. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014 Jul;69(7):616–622.• A paper indicating that roflumilast only provides a net benefit to patients at a high risk of severe exacerbations.
17. Y.Samyshkin, M.Schlunegger, S.Haefliger, et al. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis. 2013;8:79–87.
18. Y.Samyshkin, R.W.Kotchie, A.C.Mork, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ HEPAC Health Econ Prev Care. 2014 Jan;15(1):69–82.
19. K.Moll, S.X.Sun, J.J.Ellis, et al. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly medicare advantage population. Int J Chron Obstruct Pulmon Dis. 2015;10:565–576.
20. D.Moher, A.Liberati, J.Tetzlaff, et al. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.
21. S.Z.Shariff, S.A.Bejaimal, J.M.Sontrop, et al. Retrieving clinical evidence:a comparison of PubMed and Google Scholar for quick clinical searches. J Med Internet Res. 2013;15(8):e164.
22. J.Luo, K.Wang, D.Liu, et al. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis. Respir Res. 2016;17(1):18.
23. J.H.Yan, W.J.Gu, L.Pan. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease:a meta-analysis. Pulm Pharmacol Ther. 2014 Feb;27(1):83–89.
24. Y.Oba, N.A.Lone. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease:a systematic review and meta-analysis. Ther Adv Respir Dis. 2013 Feb;7(1):13–24.
25. J.Chong, P.Poole, B.Leung, et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;5:CD002309.
26. A.R.Jadad, R.A.Moore, D.Carroll, et al. Assessing the quality of reports of randomized clinical trials:is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12.
27. J.A.Sterne, D.Gavaghan, M.Egger. Publication and related bias in meta-analysis:power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000 Nov;53(11):1119–1129.
28. J.A.Sterne, M.Egger. Funnel plots for detecting bias in meta-analysis:guidelines on choice of axis. J Clin Epidemiol. 2001 Oct;54(10):1046–1055.
29. M.Egger, G.D.Smith, M.Schneider, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
30. M.Borenstein. Introduction to meta-analysis. Chichester, U.K.:John Wiley & Sons; 2009.
31. J.DeCoster. Meta-analysis notes. [cited 2016 Mar 30]. Available from:http://www.stat-help.com/meta.pdf.
32. J.R.Turner, T.A.Durham. Meta-methodology:conducting and reporting meta-analyses. J Clin Hypertens (Greenwich). 2014 Feb;16(2):91–93.
33. M.Cazzola, L.Calzetta, C.Page, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations:a meta-analysis. Eur Respir Rev. 2015 Sep;24(137):451–461.
34. S.Lewis, M.Clarke. Forest plots:trying to see the wood and the trees. BMJ. 2001 Jun 16;322(7300):1479–1480.
35. B.C.Wallace, I.J.Dahabreh, T.A.Trikalinos, et al. Closing the gap between methodologists and end-users:R as a computational back-end. J Stat Softw. 2012;49(5):1–15.
36. W.Viechtbauer. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2012;36(3):1–48.
37. J.P.Higgins, S.G.Thompson, J.J.Deeks, et al. Measuring inconsistency in meta-analyses. Bmj. 2003 Sep 6;327(7414):557–560.
38. K.Thorlund, G.Imberger, M.Walsh, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis–a simulation study. PLoS One. 2011;6(10):e25491.
39. G.H.Guyatt, A.D.Oxman, R.Kunz, et al. GRADE guidelines 6. Rating the quality of evidence–imprecision. J Clin Epidemiol. 2011 Dec;64(12):1283–1293.
40. F.J.Martinez, P.M.Calverley, U.M.Goehring, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT):a multicentre randomised controlled trial. Lancet. 2015 Mar 7;385(9971):857–866.
41. J.M.Wells, P.L.Jackson, L.Viera, et al. A randomized, placebo-controlled trial of roflumilast. Effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 Oct 15;192(8):934–942.
42. J.Zheng, J.Yang, X.Zhou, et al. Roflumilast for the treatment of COPD in an Asian population:a randomized, double-blind, parallel-group study. Chest. 2014 Jan;145(1):44–52.
43. D.E.O’Donnell, D.Bredenbroker, M.Brose, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012 May;39(5):1104–1112.
44. S.I.Rennard, P.M.Calverley, U.M.Goehring, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast–the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
45. S.D.Lee, D.S.Hui, A.A.Mahayiddin, et al. Roflumilast in Asian patients with COPD:a randomized placebo-controlled trial. Respirology. 2011 Nov;16(8):1249–1257.
46. L.M.Fabbri, P.M.Calverley, J.L.Izquierdo-Alonso, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators:two randomised clinical trials. Lancet. 2009 Aug 29;374(9691):695–703.
47. P.M.Calverley, K.F.Rabe, U.M.Goehring, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease:two randomised clinical trials. Lancet. 2009 Aug 29;374(9691):685–694.
48. K.F.Rabe, E.D.Bateman, D.O’Donnell, et al. Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease:a randomised controlled trial. Lancet. 2005 Aug 13–19; 366(9485):563–571.• The first paper, which proved that roflumilast was a promising candidate for anti-inflammatory COPD treatment because it improved lung function and reduced exacerbations compared with placebo.
49. P.M.Calverley, F.Sanchez-Toril, A.McIvor, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 Jul 15;176(2):154–161.
50. W.B.White, G.E.Cooke, P.R.Kowey, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013 Sep;144(3):758–765.•• The only analysis specifically designed to assess the cardiovascular safety of roflumilst.
51. M.Cazzola, S.Picciolo, M.G.Matera. Roflumilast in chronic obstructive pulmonary disease:evidence from large trials. Expert Opin Pharmacother. 2010 Feb;11(3):441–449.
52. W.Q.Gan, S.F.Man, A.Senthilselvan, et al. Association between chronic obstructive pulmonary disease and systemic inflammation:a systematic review and a meta-analysis. Thorax. 2004 Jul;59(7):574–580.
53. D.P.Tashkin. Roflumilast:the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother. 2014 Jan;15(1):85–96.
54. M.Cazzola, W.MacNee, F.J.Martinez, et al. Outcomes for COPD pharmacological trials:from lung function to biomarkers. Eur Respir J. 2008 Feb;31(2):416–469.
55. V.Vassiluou. Roflumilast for chronic obstructive pulmonary disease. Comment on Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease:a randomised controlled trial. Lancet. 2005;366(9500):1846.
56. J.Rho, N.Ho, V.Prasad. Counterpoint:were industry-sponsored roflumilast trials appropriate? No. CHEST J. 2014;145(5):939–942.
57. S.Gupta. Side-effects of roflumilast. Lancet. 2012;379(9817):710–711.
58. B.Beghe, K.F.Rabe, L.M.Fabbri. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med. 2013 Aug 1;188(3):271–278.
59. M.Munoz-Esquerre, M.Diez-Ferrer, C.Monton, et al. Roflumilast added to triple therapy in patients with severe COPD:a real life study. Pulm Pharmacol Ther. 2015 Feb;30:16–21.• A real life study indicating the high treatment discontinuation due to the very high incidence of adverse events such as nausea, diarrhea, and weight loss.
60. K.F.Rabe. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53–67.
61. K.P.Garnock-Jones. Roflumilast:a review in COPD. Drugs. 2015;75(14):1645–1656.
62. Center for Drug Evaluation and Research. Application number 022522Orig1s000:medical review(s). [cited 2016 Mar30]. Available from:http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000MedR.pdf•• This paper includes the analysis that demonstrated that there was not a statistically significant difference in suicidal events in patients receiving roflumilast compared to placebo.
63. US Food and Drug Administration. Analysis of malignancy for rofl umilast 500 mcg group vs placebo. [cited 2016 Mar30]. Available from:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/%20Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM208710.pdf
64. S.Siddiqui, Response To:Y.Oba, N.Lone. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease:a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7:13–24. Ther Adv Respir Dis 2013;7(4):247
65. Forest Laboratories, Inc. Daliresp prescribing information. [cited 2016 Mar30]. Available from:http://pi.actavis.com/data_stream.asp?product_group=1912&p=pi&language=E 2011.
66. A.Robichaud, P.B.Stamatiou, S.L.Jin, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002 Oct;110(7):1045–1052.
67. B.Omar, E.Zmuda-Trzebiatowska, V.Manganiello, et al. Regulation of AMP-activated protein kinase by cAMP in adipocytes:roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell Signal. 2009 May;21(5):760–766.
68. W.K.Ong, F.M.Gribble, F.Reimann, et al. The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol. 2009 Jun;157(4):633–644.
69. A.Astrup, S.Rossner, L.Van Gaal, et al. Effects of liraglutide in the treatment of obesity:a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606–1616.
70. P.E.Losco, E.W.Evans, S.A.Barat, et al. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol. 2004 May–Jun;32(3):295–308.
71. E.F.Wouters, D.Bredenbroker, P.Teichmann, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 Sep;97(9):E1720–5.
72. C.Moon, W.Zhang, N.Sundaram, et al. Drug-induced secretory diarrhea:a role for CFTR. Pharmacol Res. 2015;102:107–112.
73. J.L.Larson, M.V.Pino, L.E.Geiger, et al. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol. 1996 Jan;78(1):44–49.
74. B.J.Lipworth. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005 Jan 8–14;365(9454):167–175.
75. C.D.Manning, M.Burman, S.B.Christensen, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999 Dec;128(7):1393–1398.
76. A.Hatzelmann, C.Schudt. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001 Apr;297(1):267–279.
77. S.Liu, A.Veilleux, L.Zhang, et al. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther. 2005 Aug;314(2):846–854.
78. J.A.Lambert, S.V.Raju, L.P.Tang, et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol. 2014 Mar;50(3):549–558.
79. P.Linsdell. Cystic fibrosis transmembrane conductance regulator chloride channel blockers:pharmacological, biophysical and physiological relevance. World J Biol Chem. 2014 Feb 26;5(1):26–39.
80. W.Zhang, N.Fujii, A.P.Naren. Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas. Future Med Chem. 2012 Mar;4(3):329–345.
81. J.R.Thiagarajah, E.A.Ko, L.Tradtrantip, et al. Discovery and development of antisecretory drugs for treating diarrheal diseases. Clin Gastroenterol Hepatol. 2014 Feb;12(2):204–209.
82. A.J.Sutton, N.J.Cooper, P.C.Lambert, et al. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res. 2002 Aug;2(4):367–379.
83. E.Schechtman. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat–which of these should we use? Value Health. 2002 Sep–Oct;5(5):431–436.
84. M.Cazzola, L.Calzetta, G.Bettoncelli, et al. Cardiovascular disease in asthma and COPD:a population-based retrospective cross-sectional study. Respir Med. 2012 Feb;106(2):249–256.
85. S.Suissa, K.F.Rabe. Point:were industry-sponsored roflumilast trials appropriate? Yes. CHEST J. 2014;145(5):937–939.
86. A.Segreti, E.Stirpe, P.Rogliani, et al. Defining phenotypes in COPD:an aid to personalized healthcare. Mol Diagn Ther. 2014; 18(4):381–388.
87. P.Rogliani, L.Calzetta, A.Segreti, et al. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol. 2014 Dec;51(6):933–940.
88. M.Cazzola, L.Calzetta, P.Rogliani, et al. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2016 May;21:1–12.
89. M.G.Matera, V.Cardaci, M.Cazzola, et al. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015 Apr;14(4):533–541.
90. E.F.Wouters, D.S.Postma, B.Fokkens, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration:a randomised controlled trial. Thorax. 2005 Jun;60(6):480–487.